More on Celgene (CELG) Q1 earnings: REVLIMD sales +16% Y/Y to $1B, light of consensus of $1.1B....


More on Celgene (CELG) Q1 earnings: REVLIMD sales +16% Y/Y to $1B, light of consensus of $1.1B. ABRAXANE sales of $123M and VIDAZA of $204M inline. SG&A expenses of $333M, +11.3%. Purchased approximately 4.2M shares at cost of $403M (average price $95.95). FY2013 EPS guidance raised to $5.55-$5.65 from $5.50-$5.60. Shares -0.9% premarket. Conference call at 9 ET. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs